TLP Group LLC Buys 3,955 Shares of Bristol-Myers Squibb Co (BMY)

TLP Group LLC grew its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 120.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,243 shares of the biopharmaceutical company’s stock after purchasing an additional 3,955 shares during the quarter. TLP Group LLC’s holdings in Bristol-Myers Squibb were worth $458,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of BMY. W.G. Shaheen & Associates DBA Whitney & Co acquired a new position in shares of Bristol-Myers Squibb in the first quarter worth about $101,000. Institutional & Family Asset Management LLC acquired a new position in shares of Bristol-Myers Squibb in the first quarter worth about $106,000. Delphi Private Advisors LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $108,000. Centerpoint Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 373.1% in the first quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 1,399 shares in the last quarter. Finally, NuWave Investment Management LLC acquired a new position in shares of Bristol-Myers Squibb in the fourth quarter worth about $119,000. Institutional investors own 71.37% of the company’s stock.

In other Bristol-Myers Squibb news, Director Dinesh C. Paliwal acquired 4,770 shares of the firm’s stock in a transaction that occurred on Monday, April 30th. The stock was acquired at an average cost of $52.40 per share, with a total value of $249,948.00. Following the acquisition, the director now directly owns 8,027 shares of the company’s stock, valued at approximately $420,614.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.12% of the company’s stock.

Several research firms recently commented on BMY. BMO Capital Markets cut their price target on Bristol-Myers Squibb from $51.00 to $47.00 and set an “underperform” rating on the stock in a research note on Wednesday, April 18th. Credit Suisse Group set a $58.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Thursday, April 26th. TheStreet cut Bristol-Myers Squibb from a “b” rating to a “c+” rating in a research note on Thursday, March 8th. Morgan Stanley cut Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $54.08 to $58.00 in a research note on Tuesday, April 17th. Finally, UBS Group cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and set a $57.00 price objective on the stock. in a research note on Monday, May 21st. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $62.84.

Shares of Bristol-Myers Squibb traded down $0.03, hitting $53.43, during trading on Thursday, Marketbeat.com reports. 26,783 shares of the company traded hands, compared to its average volume of 8,464,142. The firm has a market capitalization of $86.83 billion, a PE ratio of 17.82, a price-to-earnings-growth ratio of 1.39 and a beta of 0.95. Bristol-Myers Squibb Co has a one year low of $49.96 and a one year high of $70.05. The company has a current ratio of 1.52, a quick ratio of 1.39 and a debt-to-equity ratio of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.09. The company had revenue of $5.19 billion during the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a return on equity of 37.56% and a net margin of 4.37%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.84 earnings per share. analysts predict that Bristol-Myers Squibb Co will post 3.43 EPS for the current fiscal year.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit